Have you been paying attention to shares of Quest Diagnostics (DGX) ? Shares have been on the move with the stock up 6.3% over the past month. The stock hit a new 52-week high of $153.07 in the previous session. Quest Diagnostics has gained 10.9% since the start of the year compared to the 11.2% move for the Zacks Medical sector and the 15.1% return for the Zacks Medical - Outpatient and Home Healthcare industry. What's Driving the Outperformance? The stock has an impressive record of positive earnings surp ...

Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND, Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of the nation's leading nonprofit health systems and academic medical centers, today announced a definitive agreement for Quest to acquire select assets of University Hospitals' outreach laboratory services business. ...

Company Overview - Quest Diagnostics has launched 13 blood tests aimed at evaluating micronutrient deficiencies, available for consumer purchase exclusively on questhealth.com [1] - The tests are priced between $65 and $299, with plans to introduce more tests in the near future [2] Relevance of the Tests - Micronutrient deficiencies are common and can result from food allergies, dietary restrictions, certain medications, or chronic health conditions, with at least one in three Americans at risk [3] - Approximately 48.6% of individuals have used at least one prescription drug in the past 30 days, and 60% of Americans live with at least one chronic disease, both of which are linked to potential micronutrient deficiencies [4] Industry Prospects - The vitamin test market was valued at $0.52 billion in 2023 and is projected to grow at a CAGR of 4.3% by 2032, driven by increasing consumer awareness and demand for personalized health solutions [7] Recent Developments - A study by Quest Diagnostics and the University of Alabama highlighted gaps in laboratory testing and treatment for STIs among pregnant women, indicating a need for improved adherence to testing guidelines [8][9] - The company previously launched a Vitamin & Nutrition lab test category targeting consumers with specific dietary lifestyles [6]

SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes due 2027 (the "2027 notes"), $600 million aggregate principal amount of its 4.625% senior notes due 2029 (the "2029 notes") and $850 million aggregate principal amount of its 5.000% senior notes due 2034 (the "2034 notes," and together with t ...

Quest Diagnostics (DGX) , in collaboration with the University of Alabama, conducted a study that suggests adherence to guideline-based laboratory testing and treatment of pregnant women for two of the most prevalent sexually transmitted infections (STIs) is suboptimal in the United States. This could potentially result in dire effects on maternal and newborn health. The study, titled "Chlamydia and gonorrhea testing in pregnancy: Time to improve adherence and update recommendations", was published in the p ...

Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions SECAUCUS, N.J., Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions. At least one in thre ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a variety of methods, including tried- ...

Quest Diagnostics (DGX) is gaining from strong existing customer relationships, new customer wins, broad health plan access and advanced diagnostics offerings. The stock carries a Zacks Rank #2 (Buy) currently. Quest Diagnostics has been experiencing robust volume growth in its core business (excluding COVID Testing), banking on the growth of new physician and hospital customers, a more favorable test mix with increased use of advanced diagnostics, continued strength in healthcare utilization and the ongoin ...

Quest Diagnostics Inc.'s (DGX) sustained growth momentum within the legacy base business is poised to help it grow in the upcoming quarters. Strong progress in the company's highly specialized Advanced Diagnostics offerings is encouraging. Additionally, the cost discipline program, Invigorate, is boosting productivity through automation and AI. However, a debt-laden balance sheet and challenges from fierce competition are concerning for DGX's operations. In the past year, this Zacks Rank #2 (Buy) stock has ...

Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J., Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD). Quest Diagnostics Named a 'Best Place to Work for Disability Inclusion' fo ...